Definium Therapeutics (NASDAQ:DFTX) CEO Sells $721,732.62 in Stock

Definium Therapeutics, Inc. (NASDAQ:DFTX) CEO Robert Barrow sold 19,023 shares of the stock in a transaction dated Thursday, September 3rd. The stock was sold at an average price of $37.94, for a total transaction of $721,732.62. Following the sale, the chief executive officer directly owned 1,494,640 shares in the company, valued at $56,706,641.60. This represents a 1.26% decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through this link.

Robert Barrow also recently made the following trade(s):

• On Thursday, June 25th, Robert Barrow sold 29,208 shares of Definium Therapeutics stock. The shares were sold at an average price of $45.03, for a total transaction of $1,315,236.24.

Definium Therapeutics Stock Up 0.2%

DFTX traded up $0.09 during trading hours on Friday, hitting $38.09. 1,128,691 shares of the company’s stock were exchanged, compared to its average volume of 2,216,272. Definium Therapeutics, Inc. has a 12-month low of $8.77 and a 12-month high of $49.70. The firm has a 50 day moving average of $43.70 and a 200 day moving average of $29.49. The firm has a market cap of $5.12 billion, a P/E ratio of -11.10 and a beta of 2.23. The company has a current ratio of 6.95, a quick ratio of 6.95 and a debt-to-equity ratio of 0.04.

Definium Therapeutics (NASDAQ:DFTX) last posted its quarterly earnings results on Thursday, August 6th. The company reported ($1.44) EPS for the quarter, missing the consensus estimate of ($0.55) by ($0.89). Analysts predict that Definium Therapeutics, Inc. will post -3.02 EPS for the current fiscal year.

Institutional Trading of Definium Therapeutics

Institutional investors have recently modified their holdings of the stock. California State Teachers Retirement System purchased a new position in shares of Definium Therapeutics in the 2nd quarter valued at $283,999,000. Avoro Capital Advisors LLC purchased a new stake in Definium Therapeutics in the fourth quarter valued at $66,950,000. Commodore Capital LP lifted its position in Definium Therapeutics by 10.5% in the second quarter. Commodore Capital LP now owns 5,000,000 shares of the company’s stock valued at $32,450,000 after acquiring an additional 475,000 shares during the last quarter. Wellington Management Group LLP acquired a new stake in shares of Definium Therapeutics during the second quarter worth about $138,755,000. Finally, Janus Henderson Group PLC lifted its holdings in shares of Definium Therapeutics by 8,513.2% in the 4th quarter. Janus Henderson Group PLC now owns 2,411,696 shares of the company’s stock valued at $32,256,000 after purchasing an additional 2,383,696 shares during the last quarter. Hedge funds and other institutional investors own 27.91% of the company’s stock.

Analysts Set New Price Targets

DFTX has been the topic of a number of recent research reports. Canaccord Genuity Group set a $64.00 target price on shares of Definium Therapeutics and gave the stock a “buy” rating in a research note on Thursday, August 13th. JonesTrading increased their price objective on shares of Definium Therapeutics from $74.00 to $90.00 and gave the company a “buy” rating in a research report on Thursday, August 13th. Piper Sandler reaffirmed an “overweight” rating and set a $75.00 price objective (up from $73.00) on shares of Definium Therapeutics in a research report on Friday, August 7th. Maxim Group set a $55.00 target price on shares of Definium Therapeutics and gave the stock a “buy” rating in a research note on Friday, August 14th. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of Definium Therapeutics in a report on Friday, July 17th. Two research analysts have rated the stock with a Strong Buy rating, seventeen have given a Buy rating and one has issued a Sell rating to the company. According to MarketBeat.com, the company presently has an average rating of “Buy” and an average price target of $63.00.

Definium Therapeutics Company Profile

Definium Therapeutics, Inc, a clinical stage biopharmaceutical company, develops novel products to treat brain health disorders. The company’s lead product candidates include MM120, which is in phase 3 for the treatment of generalized anxiety disorder and attention deficit hyperactivity disorder; and DT402, a R-enantiomer of 3,4-methylenedioxymethamphetamine, which is in phase 2a clinical trials for the treatment of core symptoms of autism spectrum disorder. The company was formerly known as Mind Medicine (MindMed) Inc and changed its name to Definium Therapeutics, Inc in January 2026.